Angiostatin Kringles 1-4 (PLG) Active Protein

Name: PLG Active Protein; Angiostatin Kringles 1-4; Research Grade; MyBioSource
Brand: MyBioSource
SKU: MBS634949
Price: 905 USD
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS634949

Purified human Kringles 1-4 (MW ~50kD doublet) is prepared from human fluids negative for HBsAg, HIV, and HCV. More details

$905 / 0.1 mg +1 FREE 8GB USB

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

Angiostatin Kringles 1-4 (Plg), Active Protein

Full Product Name

Angiostatin Kringles 1-4, Human

Product Gene Name

Plg active protein

Host

Human fluid.

Form/Format

Supplied as a liquid in 20mM Hepes, 40mM sodium chloride, pH 8.0.

Purity/Purification

Highly Purified
~ 98% (SDS-PAGE)

Concentration

1mg/ml (lot specific)

Preparation and Storage

Aliquot to avoid repeated freezing and thawing and store at -70 degree C. Aliqots are stable for 6 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Molecular Weight

50kD

Chromosome Location

Chromosome: 17; NC_000083.6 (12378609..12419384). Location: 17 A1; 17 8.5 cM

3D Structure

ModBase 3D Structure for P20918

Active Protein Note

Protein activity can be an ambiguous term. Please refer to the data sheet or inquire with Technical Support to determine the definition of activity for this product.

Activity

Biologically active. Human angiostatin significantly inhibits bFGF-induced endothelial cell proliferation and migration at concentration ranging from 300nM-1uM.
Embryonic vascular system undergoes a series of complex, highly regulated series of events involving differentiation, migration and association of primitive endothelial cells. This process is termed vasculogenesis. A further remodeling of the primitive vascular system forms the mature cardiovascular system. This process is known as angiogenesis (sprouting of new capillary vessels from pre-existing vasculature). Angiogenesis accounts for the formation of vasculature into previously avascular organs such as brain and kidney. Angiogenic activity in the adult is required during the normal tissue repair, and for the remodeling of the female reproductive organs (ovulation and placental development). Certain pathological conditions, such as tumor growth and diabetic retinopathy, also require angiogenesis.
Recent studies have identified several proteolytic fragments or cryptic domains of proteins that act as inhibitors of angiogenesis. These include fragments of plasminogen such as Angiostatin protein (kringles 1-4) and kringles 1-5, C-terminal proteolytic fragment of Collagen XVIII (Endostatin protein), the NC10 domain of collagen 15 (Restin), the C-terminal hemopexin-like domain of MMP-2 (PEX), the N-terminal fragment of prolactin, and the N-terminally truncated platelet factor. Angiostatin protein, a proteolytic fragment of plasminogen, is comprised of the first four kringle regions. It prevents the growth of endothelial cells, and its systemic administration inhibits the growth of primary carcinomas in mice. Kringles 1-3 fragment has a greater inhibitory activity than the Kringles 1-4 fragment. The protease-activated Kringles 1-5 is the most potent plasminogen fragment with over 50-fold greater endothelial cell specific inhibitory activity. Its systemic administration inhibited the growth of fibrosarcoma and significantly reduced neovascularization.

Product Categories/Family for Plg active protein

Molecular Biology; MB-Coagulation Factors

Applications Tested/Suitable for Plg active protein

ELISA (EL/EIA)

Other Notes

Small volumes of Plg active protein vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Plg purchase

MBS634949 is an active protein targeting Plg. Also known as Angiostatin Kringles 1-4, Human. Host: Human fluid.

Additional Details

NCBI/Uniprot data below describe general gene information for Plg. It may not necessarily be applicable to this product.

NCBI GI #

38000582

NCBI GeneID

18815

NCBI Accession #

AAR07361.1

UniProt Primary Accession #

P20918

UniProt Secondary Accession #

Q8CIS2; Q91WJ5

UniProt Related Accession #

P20918

NCBI Official Full Name

angiostatin

NCBI Official Synonym Full Names

plasminogen

NCBI Official Symbol

Plg

NCBI Official Synonym Symbols

Pg; AI649309

UniProt Protein Name

Plasminogen

Protein Family

Plasminogen

UniProt Gene Name

Plg

UniProt Entry Name

PLMN_MOUSE

NCBI Protein Information

plasminogen; angiostatin; plasmin heavy chain A; plasmin light chain B

UniProt Comments for Plg

Plasminogen: Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells. Defects in PLG are the cause of plasminogen deficiency (PLGD). PLGD is characterized by decreased serum plasminogen activity. Two forms of the disorder are distinguished: type 1 deficiency is additionally characterized by decreased plasminogen antigen levels and clinical symptoms, whereas type 2 deficiency, also known as dysplasminogenemia, is characterized by normal, or slightly reduced antigen levels, and absence of clinical manifestations. Plasminogen deficiency type 1 results in markedly impaired extracellular fibrinolysis and chronic mucosal pseudomembranous lesions due to subepithelial fibrin deposition and inflammation. The most common clinical manifestation of type 1 deficiency is ligneous conjunctivitis in which pseudomembranes formation on the palpebral surfaces of the eye progresses to white, yellow-white, or red thick masses with a wood-like consistency that replace the normal mucosa. Belongs to the peptidase S1 family. Plasminogen subfamily.

Protein type: Secreted; EC 3.4.21.7; Motility/polarity/chemotaxis; Protease; Secreted, signal peptide

Cellular Component: extrinsic to plasma membrane; extracellular space; extrinsic to external side of plasma membrane; cell surface; intracellular membrane-bound organelle; cell; plasma membrane; extracellular region

Molecular Function: peptidase activity; protein domain specific binding; hydrolase activity; serine-type peptidase activity; serine-type endopeptidase activity; endopeptidase activity; apolipoprotein binding; catalytic activity; receptor binding

Biological Process: tissue remodeling; proteolysis; myoblast differentiation; muscle maintenance; extracellular matrix disassembly; fibrinolysis; negative regulation of angiogenesis; negative regulation of fibrinolysis; proteolysis involved in cellular protein catabolic process; tissue regeneration; hemostasis; positive regulation of fibrinolysis; blood coagulation

Research Articles on Plg

1. These findings highlight a critical role for plasmin in the catabolism of aggregated LDL by macrophages and provide a new context for considering the atherogenic role of plasmin.

Precautions

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

Disclaimer

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.

Product Note

Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual, it is intended to serve as an example only. Please refer to the instructions For Use provided with the assay kit for precise details.

Product PubMed Publications

Pathways associated with Plg active protein

Products by Pathway	Pathway Diagram
Activation Of Matrix Metalloproteinases Pathway antibodies	Activation Of Matrix Metalloproteinases Pathway Diagram
Blood Clotting Cascade Pathway antibodies	Blood Clotting Cascade Pathway Diagram
Complement And Coagulation Cascades Pathway antibodies	Complement And Coagulation Cascades Pathway Diagram
Complement And Coagulation Cascades Pathway antibodies	Complement And Coagulation Cascades Pathway Diagram
Complement And Coagulation Cascades Pathway antibodies	Complement And Coagulation Cascades Pathway Diagram
Degradation Of The Extracellular Matrix Pathway antibodies	Degradation Of The Extracellular Matrix Pathway Diagram
Dissolution Of Fibrin Clot Pathway antibodies	Dissolution Of Fibrin Clot Pathway Diagram
Extracellular Matrix Organization Pathway antibodies	Extracellular Matrix Organization Pathway Diagram
Hemostasis Pathway antibodies	Hemostasis Pathway Diagram
Influenza A Pathway antibodies	Influenza A Pathway Diagram

Diseases associated with Plg active protein

Disease Name	Pubmed Publications
Cardiovascular Diseases Antibodies	>104 publications with Plg and Cardiovascular Diseases
Thrombosis Antibodies	>86 publications with Plg and Thrombosis
Nervous System Diseases Antibodies	>82 publications with Plg and Nervous System Diseases
Brain Diseases Antibodies	>55 publications with Plg and Brain Diseases
Inflammation Antibodies	>45 publications with Plg and Inflammation
Liver Diseases Antibodies	>37 publications with Plg and Liver Diseases
Blood Coagulation Disorders Antibodies	>31 publications with Plg and Blood Coagulation Disorders
Hemorrhage Antibodies	>23 publications with Plg and Hemorrhage
Venous Thrombosis Antibodies	>20 publications with Plg and Venous Thrombosis
Necrosis Antibodies	>19 publications with Plg and Necrosis

Organs/Tissues associated with Plg active protein

Organ/Tissue Name	Pubmed Publications
Other Antibodies	>190 publications with Plg and Other
Liver Antibodies	>76 publications with Plg and Liver
Muscle Antibodies	>47 publications with Plg and Muscle
Lung Antibodies	>41 publications with Plg and Lung
Embryonic Tissue Antibodies	>20 publications with Plg and Embryonic Tissue
Intestine Antibodies	>10 publications with Plg and Intestine